Cheung B M Y
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong.
Hong Kong Med J. 2002 Jun;8(3):185-91.
The renin-angiotensin-aldosterone system plays a key role in the regulation of fluid and electrolyte balance. Angiotensin-converting enzyme inhibitors inhibit angiotensin-converting enzyme and have been shown to be effective in many cardiovascular diseases. They should be considered for the treatment of hypertension in patients with heart failure, previous myocardial infarction, diabetes, or proteinuria. There are a number of side-effects associated with angiotensin-converting enzyme inhibitors, especially persistent dry cough. Angiotensin II receptor antagonists (sartans) provide a more specific blockade of the renin-angiotensin-aldosterone system and are associated with fewer side-effects, including cough. Their long-term efficacy and tolerability in the treatment of patients with hypertension has, however, yet to be established. Periodic monitoring of renal function and electrolytes is required in patients treated with an angiotensin-converting enzyme inhibitor or a sartan.
肾素-血管紧张素-醛固酮系统在体液和电解质平衡调节中起关键作用。血管紧张素转换酶抑制剂可抑制血管紧张素转换酶,已被证明在许多心血管疾病中有效。对于心力衰竭、既往心肌梗死、糖尿病或蛋白尿患者的高血压治疗,应考虑使用此类药物。血管紧张素转换酶抑制剂存在多种副作用,尤其是持续性干咳。血管紧张素II受体拮抗剂(沙坦类)能更特异性地阻断肾素-血管紧张素-醛固酮系统,且副作用较少,包括咳嗽。然而,其在高血压患者治疗中的长期疗效和耐受性尚未确立。使用血管紧张素转换酶抑制剂或沙坦类药物治疗的患者需要定期监测肾功能和电解质。